Medications for type 2 diabetes: how will we be treating patients in 50 years?
Open Access
- 14 March 2015
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 58 (8), 1735-9
- https://doi.org/10.1007/s00125-015-3541-8
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Outpatient Glycemic Control with a Bionic Pancreas in Type 1 DiabetesThe New England Journal of Medicine, 2014
- Peer Support in Health Care and Prevention: Cultural, Organizational, and Dissemination IssuesAnnual Review of Public Health, 2014
- Restoring Insulin Secretion (RISE): Design of Studies of β-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life SpanDiabetes Care, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2013
- Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)Diabetes Care, 2013
- Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes StudyThe Lancet, 2012
- Implementation of the Department of Veterans Affairs' first point-of-care clinical trialJournal of the American Medical Informatics Association, 2012
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyThe New England Journal of Medicine, 2006
- Abstracts of the IDF Congress in Paris 2003Diabetologia, 2003